about
CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive ReviewExtending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization)Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinomaManagement of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 20162014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaEffect of transcatheter intraarterial therapies on the distribution of Doxorubicin in liver cancer in a rabbit modelEvaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result.Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoringOutcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma.Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Hypoxia as a target for drug combination therapy of liver cancer.Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.Current management of hepatocellular carcinoma.Cirrhosis and its complications: evidence based treatment.The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysisBland embolization versus chemoembolization of hepatocellular carcinoma before transplantationRelevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients.Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function.High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results.Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolizationChemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRIHepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samplesEfficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.Embolization of liver tumors: Past, present and future.Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumorigenicity.Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma.Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings.
P2860
Q26770014-3DF78258-A68B-442C-8DE5-BFAEE64DCA4CQ26796524-145F93CA-73B6-4A12-8E64-1918881B8AFEQ26851627-896596B2-7F83-4D88-90CE-4B7969045590Q26851788-C66B9E50-57B9-4F21-9C89-F2FDF53E2343Q28072595-91706516-FCC4-4988-A274-6B1480E3ECA7Q28392783-3F74836D-B765-43DC-A52B-71D45F80BFC6Q28394414-9F9A4B8E-EA68-4DD0-9F74-FE41A1F1DEE8Q28534244-66D2021C-EB95-4A45-A6D6-E8A750092410Q30365378-451F1948-E6FC-4648-8D78-DA83B8DD2862Q30380915-3D30AFBE-DE02-4ABB-98D1-D3162D0E5C16Q30436747-F87021A3-0650-4BAC-89FE-AF4212A34F84Q30460588-69E00E8C-647A-41CC-A9EB-72F5002E3AA5Q30468280-F328EC4F-0770-464C-87BD-AC171F6166F3Q30479629-28773615-8D73-4E91-9DE2-6CECD576F385Q30491780-ECA851B1-9848-4F67-AD59-2980566C45C4Q33376718-8CD73A4F-FFF7-4F0F-9B12-2BB69B518F80Q33582165-9932A38F-689C-419F-9B60-E7B818427671Q33594931-029C1FA2-9494-4BE0-BFC0-F077C18D14D6Q33686817-EED181DC-B7CA-4361-9F4E-8BF7073239D9Q33746790-485F095E-B4BF-40C5-844F-A2C0AE0F720DQ33778970-6C826599-D67D-424D-9942-C7AA8B724109Q33893756-6865322B-E307-4C15-87BB-A305D6258566Q33913086-2E9D1332-EFF8-4A71-AFE7-9C6CB71E93C5Q33919629-357A0068-0971-40C7-9C75-63F322049A2DQ33929679-5C8397E5-81FD-4ECE-A855-A9E64ED55557Q34025631-D577FD9A-C763-407B-AC8D-333181462629Q34065098-EAA5EB43-D9E6-4A05-A4F6-BF7F76496FE4Q34067946-CD7CCA07-9E9A-4604-8725-90D6354ED446Q34089545-891BB42F-397A-4026-8EB2-A93AD272EA42Q34098540-75EC4380-A786-418C-95C6-D6E528A207CEQ34131801-CAE15335-7CF5-4B7F-9E80-31CF1BF547D8Q34224698-CCFEF595-A49A-46F8-A40D-BF69A3DF5AB7Q34224741-3E22FF22-77E9-4B26-95A9-47E81F9AA067Q34225706-594ED802-E52A-4FE1-BBD4-027D5054181BQ34302900-92162ADA-86EE-42EB-A21B-4A9520C2B29FQ34371623-DFEAE63B-A618-4099-B37C-D00A2EAB27E0Q34394479-33FD9406-A136-41CF-9FF2-12DA45E6A10DQ34409128-D4986CC8-FAD2-4093-8BC4-04E99573D30FQ34412656-9EEB2E26-B803-48B3-AE2D-C96E59A46E48Q34606217-59A87E8C-17CB-4374-9EBD-9C6FB6EA4322
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Chemoembolization for hepatocellular carcinoma.
@ast
Chemoembolization for hepatocellular carcinoma.
@en
Chemoembolization for hepatocellular carcinoma.
@nl
type
label
Chemoembolization for hepatocellular carcinoma.
@ast
Chemoembolization for hepatocellular carcinoma.
@en
Chemoembolization for hepatocellular carcinoma.
@nl
prefLabel
Chemoembolization for hepatocellular carcinoma.
@ast
Chemoembolization for hepatocellular carcinoma.
@en
Chemoembolization for hepatocellular carcinoma.
@nl
P1433
P1476
Chemoembolization for hepatocellular carcinoma.
@en
P2093
Jordi Bruix
Margarita Sala
P304
P356
10.1053/J.GASTRO.2004.09.032
P407
P433
P577
2004-11-01T00:00:00Z